Mary Lawrence, MD
Endocrinology, Diabetes & Metabolism · Morehead City, NCNPI 1215932140
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $97,347 of the $131,200 with a category attached, or 74.2%. Novo Nordisk accounts for 76.8% of it on its own, with 55 other manufacturers making up the rest. Reporting peaked in 2019 at $41,774 and has fallen 66.7% since, to $13,900 in 2025.
Across 603 payments — averaging $217.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$101K
- Eli Lilly$16K
- Novo Nordisk AS$3K
- Cequr Corporation$2K
- Radius Health, Inc.$1K
- Tandem Diabetes Care, Inc.$1K
- plus $7K from 50 others
Across 1,333 payments — averaging $3633.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$3.6M
- AbbVie$458K
- Novo Nordisk AS$305K
- Sanofi US Services Inc.$227K
- Radius Health, Inc.$89K
- Akebia Therapeutics Inc$71K
- plus $137K from 5 others
What the payments were for
- Speaking & faculty fees$97,34774%
- Travel & lodging$12,69810%
- Food & beverage$19,74215%
- Education$1,3551%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$58,848
- RYBELSUS$32,549
- Tresiba$8,194
- CeQur Simplicity$1,667
- Tymlos$1,139
- t:slim X2 insulin pump$1,000
- t-slim insulin pump$300
- EVENITY$125
- Kerendia$125
- FreeStyle Libre 2$109
How this compares
$131,200 in reported general payments places this provider in the 85th percentile of 232 endocrinology, diabetes & metabolism providers in North Carolina.
See all endocrinology, diabetes & metabolism providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 366 | $521,161 |
| JardianceEmpagliflozin | 220 | $235,389 |
| RybelsusSemaglutide | 138 | $184,200 |
| FarxigaDapagliflozin Propanediol | 193 | $144,523 |
| MounjaroTirzepatide | 124 | $128,608 |
| Tresiba Flextouch U-200Insulin Degludec | 133 | $127,685 |
| TrulicityDulaglutide | 55 | $76,357 |
| ProliaDenosumab | 41 | $72,771 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 46 | $58,275 |
| EliquisApixaban | 78 | $57,402 |
| Tresiba Flextouch U-100Insulin Degludec | 115 | $55,310 |
| MyrbetriqMirabegron | 80 | $47,821 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 41 | $39,655 |
| XareltoRivaroxaban | 35 | $35,883 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 37 | $30,501 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Xultophy 100-3.6, Novolog, Fiasp | $100,722 | $794,293624 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $106 | $275,044261 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $466 | $214,148205 claims |
| AstraZenecaFarxiga | $307 | $144,523193 claims |
| AmgenProlia | $934 | $72,77141 claims |
| PfizerEliquis | $324 | $57,40278 claims |
| Astellas Pharma US IncMyrbetriq | $220 | $47,82180 claims |
| Johnson & JohnsonXarelto, Invokana | $50 | $45,94247 claims |
| MerckJanuvia, Janumet Xr | $194 | $41,74760 claims |
| GSKTrelegy Ellipta | $28 | $26,96735 claims |
| AbbVieCreon, Linzess | $418 | $26,60925 claims |
| Cequr CorporationCequr Simplicity | $1,717 | $15,86838 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 232 endocrinology, diabetes & metabolism providers in North Carolina.
Other endocrinology, diabetes & metabolism in Morehead City
- Kathryn LucasMorehead City$51K
- Mark WarrenGreenville$915K
- Thomas OconnellBurlington$805K
- Corey BerlinRaleigh$742K
- Michael FavoritoWilmington$723K
- Stephen SouthGreensboro$624K
- Richard DoddAsheville$526K
- Wendy LaneAsheville$487K
- Victor MarlarAsheville$483K
- John BuseChapel Hill$460K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.